Evidence map›Paper›PMID 36249685›Full record

ArticleOphthalmology science2022

Tumor-Infiltrating T Cells Can Be Expanded Successfully from Primary Uveal Melanoma after Separation from Their Tumor Environment.

Gülçin Gezgin, Marten Visser, Dina Ruano, Saskia J Santegoets, Noel F C C de Miranda, Pieter A van der Velden, Gregorius P M Luyten, Sjoerd H van der Burg, Els M Verdegaal, Martine J Jager

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Gülçin GezginDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
Marten VisserDepartment of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
Dina RuanoDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Saskia J SantegoetsDepartment of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
Noel F C C de MirandaDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Pieter A van der VeldenDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
Gregorius P M LuytenDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
Sjoerd H van der BurgDepartment of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
Els M VerdegaalDepartment of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
Martine J JagerDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
Leiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To evaluate whether expanded tumor-infiltrating lymphocytes (TILs) can be obtained from primary uveal melanoma (UM) for potential use as adjuvant treatment in patients at risk of developing metastatic disease. Design: Experimental research study. Participants: Freshly obtained primary UM from 30 patients. Methods: Three different methods were used to expand TILs: (1) direct culture from small fragments of fresh tumor tissue, (2) single-cell tissue preparation by enzymatic digestion and subsequent enrichment of mononuclear cells, and (3) selection of CD3 Main Outcome Measures: The feasibility of expanding TILs from primary UM, testing their reactivity to autologous UM cells, and evaluating the impact of an immunomodulatory environment. Results: Direct culture of tumor parts led to successful TIL culture in 4 of 22 tumors (18%), enrichment of mononuclear cells gave rise to TILs in 5 of 12 tumors (42%), while preselection of CD3 Conclusions: The need to separate TILs from their tumor microenvironment for their successful expansion and the presence of UM-reactive T cells among TILs suggests that these UM-reactive T cells are strongly suppressed in vivo and that UM is immunogenic. These findings indicate that adoptive TIL therapy could be an option as an adjuvant treatment in primary UM patients at high risk of developing metastatic disease.

Indexed as

BAP1, BRCA1-associated protein 1CTLA4, cytotoxic T-lymphocyte-associated protein 4IFN-γ, interferon γIL, interleukinImmunotherapyPD-1, programmed cell death protein 1TILs, tumor-infiltrating lymphocytesTIM-3, T-cell immunoglobulin and mucin-domain containing 3TME, tumor microenvironmentTumor-infiltrating lymphocytesTumor-infiltrating T cellsUM, uveal melanomaUveal melanoma

Identifiers

PMID36249685
PMCPMC9560540
OpenAlexW4214593744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.